Clinical Trial Detail

NCT ID NCT03267186
Title Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
Recruitment Recruiting
Gender
Phase Phase II
Variant Requirements No
Sponsors Andrew Rezvani
Indications

acute leukemia

acute lymphoblastic leukemia

acute myeloid leukemia

chronic myeloid leukemia

Therapies

Ibrutinib

Age Groups:

No variant requirements are available.